Efficacy and Predictors of Response to a Low‐FODMAP Diet in Patients With Overlap of Functional Dyspepsia and Irritable Bowel Syndrome: A Prospective Multicentre Randomized Clinical Trial

BACKGROUND AND AIMS: Functional dyspepsia (FD) frequently coexists with irritable bowel syndrome (IBS), resulting in a complex clinical phenotype characterized by prominent postprandial symptoms and limited treatment options. We compared the efficacy of a low-fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet with traditional dietary advice (TDA) in this population. METHODS: In this multicentre randomized, assessor-blinded trial, adults fulfilling Rome IV criteria for both FD and IBS were assigned to a low-FODMAP diet (LFD) or TDA for 6 weeks, with structured dietitian support. The primary endpoint was a combined response, defined by both a ≥ 50-point reduction in IBS Symptom Severity Scale and a ≥ 30% reduction in Short-Form Nepean Dyspepsia Index (SFNDI) symptom scores at 6 weeks. Among patients who responded to LFD, FODMAPS were systematically reintroduced from 7 to 12 weeks, and patients who had symptom recurrence were defined as 'true responders'. Baseline predictors of true LFD response were evaluated using univariable and multivariable logistic regression (CTRI/2025/04/084483). RESULTS: A total of, 112 participants were randomized (LFD, n = 59; TDA, n = 53; mean age 40.9 ± 15.2 years, 42.8% males). After 6 weeks, the combined IBS-FD response rates were 59.3% versus 32.1% (p = 0.005) in the LFD and TDA arms respectively. After FODMAP reintroduction, 32/35 patients (91.4%) had symptom recurrence (true responders). Improvements in symptom and disease-specific quality-of-life scores favoured LFD. Exploratory multivariable predictors of response to LFD were postprandial distress sub-type and a higher (worse) baseline SF-NDI quality-of-life score. CONCLUSION: A low-FODMAP diet was superior to traditional dietary advice in improving global symptoms and HRQoL in patients with FD-IBS overlap, supporting targeted fermentable carbohydrate restriction as an effective, personalized therapeutic strategy.

Authors

Institutions

Publication Details

Journal
Alimentary Pharmacology & Therapeutics
Published
2026-11-18
DOI
https://doi.org/10.1111/apt.71100
Primary Topic
Gastrointestinal motility and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy and Predictors of Response to a Low‐FODMAP Diet in Patients With Overlap of Functional Dyspepsia and Irritable Bowel Syndrome: A Prospective Multicentre Randomized Clinical Trial

Ashok Dalal, Vaishali Bhardwaj, Riya Khurana, Manjeet Kumar Goyal et al.
Alimentary Pharmacology & Therapeutics
Gastrointestinal motility and disorders
article

Efficacy and Predictors of Response to a Low‐FODMAP Diet in Patients With Overlap of Functional Dyspepsia and Irritable Bowel Syndrome: A Prospective Multicentre Randomized Clinical Trial

Ashok Dalal, Vaishali Bhardwaj, Riya Khurana, Manjeet Kumar Goyal, Sanjeev Sachdeva, Omesh Goyal, Venkatesh Sudharsan Vaithiyam, Gurseen Rakhra
article en

Abstract

BACKGROUND AND AIMS: Functional dyspepsia (FD) frequently coexists with irritable bowel syndrome (IBS), resulting in a complex clinical phenotype characterized by prominent postprandial symptoms and limited treatment options. We compared the efficacy of a low-fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet with traditional dietary advice (TDA) in this population. METHODS: In this multicentre randomized, assessor-blinded trial, adults fulfilling Rome IV criteria for both FD and IBS were assigned to a low-FODMAP diet (LFD) or TDA for 6 weeks, with structured dietitian support. The primary endpoint was a combined response, defined by both a ≥ 50-point reduction in IBS Symptom Severity Scale and a ≥ 30% reduction in Short-Form Nepean Dyspepsia Index (SFNDI) symptom scores at 6 weeks. Among patients who responded to LFD, FODMAPS were systematically reintroduced from 7 to 12 weeks, and patients who had symptom recurrence were defined as 'true responders'. Baseline predictors of true LFD response were evaluated using univariable and multivariable logistic regression (CTRI/2025/04/084483). RESULTS: A total of, 112 participants were randomized (LFD, n = 59; TDA, n = 53; mean age 40.9 ± 15.2 years, 42.8% males). After 6 weeks, the combined IBS-FD response rates were 59.3% versus 32.1% (p = 0.005) in the LFD and TDA arms respectively. After FODMAP reintroduction, 32/35 patients (91.4%) had symptom recurrence (true responders). Improvements in symptom and disease-specific quality-of-life scores favoured LFD. Exploratory multivariable predictors of response to LFD were postprandial distress sub-type and a higher (worse) baseline SF-NDI quality-of-life score. CONCLUSION: A low-FODMAP diet was superior to traditional dietary advice in improving global symptoms and HRQoL in patients with FD-IBS overlap, supporting targeted fermentable carbohydrate restriction as an effective, personalized therapeutic strategy.

Alimentary Pharmacology & Therapeutics
Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar Lohia Hospital (IN), Dayanand Medical College & Hospital (IN), Govind Ballabh Pant Hospital (IN), Cleveland Clinic Akron General (US), Manav Rachna International Institute of Research and Studies (IN)
Gastrointestinal motility and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon